Musculoskeletal Partnering Terms and Agreements, New Report Launched

The Musculoskeletal Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter musculoskeletal partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors musculoskeletal technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual musculoskeletal deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For more information see - http://mrr.cm/ZQD

The initial chapters of this report provide an orientation of musculoskeletal dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in musculoskeletal dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading musculoskeletal deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of musculoskeletal deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all musculoskeletal deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all musculoskeletal partnering deals signed and announced since 2009. The chapter is organized by specific musculoskeletal therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all musculoskeletal partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in musculoskeletal partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of musculoskeletal technologies and products.

Benefits

Musculoskeletal Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of musculoskeletal deal trends since 2009
• Access musculoskeletal deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between musculoskeletal partner companies
• Comprehensive access to over 1,500 links to actual musculoskeletal deals entered into by the world’s biopharma companies
• Indepth review of musculoskeletal deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner musculoskeletal opportunities
• Uncover companies actively partnering musculoskeletal opportunities

Report scope

Musculoskeletal Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide.

Musculoskeletal Partnering Terms and Agreements includes:

• Trends in musculoskeletal dealmaking in the biopharma industry since 2009
• Analysis of musculoskeletal deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of musculoskeletal deal contract documents
• Comprehensive access to over 1,500 musculoskeletal deal records
• The leading musculoskeletal deals by value since 2009
• Most active musculoskeletal dealmakers since 2009

In Musculoskeletal Partnering Terms and Agreements, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Spanning over 1009 pages, “Musculoskeletal Partnering Terms and Agreements” report covering the Trends in musculoskeletal dealmaking, Leading musculoskeletal deals, Musculoskeletal partnering contracts directory, Musculoskeletal dealmaking by indication, Appendices.

For more information see - http://mrr.cm/ZQD